Advertisement

176 PIVOTAL RANDOMIZED-CONTROLLED TRIAL OF THE ADJUSTABLE (SPATZ-3) INTRAGASTRIC BALLOON SYSTEM FOR WEIGHT LOSS

      Lifestyle and behavioral interventions remain the foundation for obesity management. However, as standalone therapies, the rates of success are limited with marked heterogeneity in response. We aimed to determine the efficacy and safety of the 32 weeks adjustable fluid-filled intragastric balloon system (Spatz 3, Spatz FGIA, Great Neck, NY) for weight loss.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect